Find all
associated with


Refine your query (more in Advanced-Search):
 Focus on the recent 5 years   Focus on the current year   Focus on the last 30 days   More choices ...
 Focus on articles with free fulltexts   More choices ...
 Do simple 'keyword' search (no query expansion)

[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 316603
1. Fewings N, Gatt PN, McKay FC, Parnell GP, Schibeci SD, Edwards J, Basuki MA, Goldinger A, Fabis-Pedrini MJ, Kermode AG, Manrique CP, McCauley JL, Nickles D, Baranzini SE, Burke T, Vucic S, Stewart GJ, Booth DR: Data characterizing the ZMIZ1 molecular phenotype of multiple sclerosis. Data Brief; 2017 Apr;11:364-370
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Data characterizing the ZMIZ1 molecular phenotype of multiple sclerosis.
  • The data presented in this article are related to the research article entitled "The autoimmune risk gene ZMIZ1 is a vitamin D responsived marker of a molecular phenotype of multiple sclerosis" Fewings et al. (2017) [1].
  • Here we identify the set of genes correlated with ZMIZ1 in multiple cohorts, provide phenotypic details on those cohorts, and identify the genes negatively correlated with ZMIZ1 and the cells predominantly expressing those genes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2011 Aug 10;476(7359):214-9 [21833088.001]
  • [Cites] Hum Mol Genet. 2014 Mar 15;23 (6):1425-34 [24158849.001]
  • [Cites] Hum Mol Genet. 2013 Oct 15;22(20):4194-205 [23748426.001]
  • [Cites] Ann Neurol. 2011 Feb;69(2):292-302 [21387374.001]
  • [Cites] Clin Immunol. 2016 Feb;163:96-107 [26762769.001]
  • [Cites] J Autoimmun. 2017 Mar;78:57-69 [28063629.001]
  • [Cites] Clin Immunol. 2014 Mar;151(1):16-24 [24495857.001]
  • [Cites] Ann Neurol. 2011 Dec;70(6):881-6 [22190362.001]
  • [Cites] Hum Mol Genet. 2010 Jun 1;19(11):2134-43 [20190274.001]
  • [Cites] Nat Genet. 2013 Nov;45(11):1353-60 [24076602.001]
  • [Cites] Mult Scler. 2014 May;20(6):675-85 [24126065.001]
  • (PMID = 28275670.001).
  • [Journal-full-title] Data in brief
  • [ISO-abbreviation] Data Brief
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS088155
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Gene expression / Molecular phenotype / Multiple sclerosis / ZMIZ1
  •  go-up   go-down


2. Allan ERO, Campden RI, Ewanchuk BW, Tailor P, Balce DR, McKenna NT, Greene CJ, Warren AL, Reinheckel T, Yates RM: A role for cathepsin Z in neuroinflammation provides mechanistic support for an epigenetic risk factor in multiple sclerosis. J Neuroinflammation; 2017 May 10;14(1):103
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A role for cathepsin Z in neuroinflammation provides mechanistic support for an epigenetic risk factor in multiple sclerosis.
  • BACKGROUND: Hypomethylation of the cathepsin Z locus has been proposed as an epigenetic risk factor for multiple sclerosis (MS).
  • METHODS: Experimental autoimmune encephalomyelitis (EAE) was induced in both wildtype mice and mice deficient in cathepsin Z.
  • Consistently, we found that cathepsin Z-deficiency reduced the efficiency of antigen presenting cells to secrete IL-1β, which in turn reduced the ability of mice to generate Th17 responses-critical steps in the pathogenesis of EAE and MS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2497-502 [20133781.001]
  • [Cites] Biochim Biophys Acta. 2011 Feb;1812(2):246-51 [20600875.001]
  • [Cites] Biochemistry. 1999 Sep 28;38(39):12648-54 [10504234.001]
  • [Cites] Eur J Immunol. 1988 Jan;18(1):97-104 [2831066.001]
  • [Cites] Nature. 2011 Aug 10;476(7359):214-9 [21833088.001]
  • [Cites] J Immunol. 1997 Mar 15;158(6):2723-30 [9058806.001]
  • [Cites] J Proteome Res. 2010 May 7;9(5):2764-74 [20329800.001]
  • [Cites] PLoS Pathog. 2015 May 08;11(5):e1004887 [25955828.001]
  • [Cites] Sci Rep. 2014 Dec 02;4:7281 [25445147.001]
  • [Cites] J Biol Chem. 2010 Oct 29;285(44):33691-700 [20736174.001]
  • [Cites] Biochim Biophys Acta. 2009 Nov;1793(11):1656-68 [19748528.001]
  • [Cites] Eur J Immunol. 2010 May;40(5):1473-85 [20201036.001]
  • [Cites] J Biol Chem. 2006 Dec 22;281(51):39588-97 [17065156.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Jul 15;178(2):203-7 [18420963.001]
  • [Cites] Ernst Schering Res Found Workshop. 2006;(56):81-95 [16329647.001]
  • [Cites] Methods Mol Biol. 2015;1339:101-9 [26445783.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):610-21 [16467548.001]
  • [Cites] PLoS One. 2012;7(3):e32562 [22412888.001]
  • [Cites] J Immunol. 2014 Jun 1;192(11):4989-5001 [24778444.001]
  • [Cites] J Immunol. 2015 Aug 15;195(4):1685-97 [26195813.001]
  • [Cites] J Biol Chem. 1998 Jul 3;273(27):16816-23 [9642240.001]
  • [Cites] PLoS One. 2013 Jul 30;8(7):e70242 [23936173.001]
  • [Cites] J Immunol. 2010 May 1;184(9):4610-4 [20368281.001]
  • [Cites] Nat Immunol. 2008 Aug;9(8):847-56 [18604214.001]
  • [Cites] J Neuroimmunol. 2011 May;234(1-2):84-92 [21463904.001]
  • [Cites] Traffic. 2005 May;6(5):413-20 [15813751.001]
  • [Cites] J Biol Chem. 2010 Nov 12;285(46):35497-504 [20837477.001]
  • [Cites] J Neurosci Res. 2005 Jun 15;80(6):798-808 [15898103.001]
  • [Cites] Nat Neurosci. 2014 Jan;17(1):121-30 [24270187.001]
  • [Cites] FEBS Lett. 1998 Aug 28;434(1-2):135-9 [9738465.001]
  • [Cites] EMBO J. 2012 Feb 15;31(4):932-44 [22157818.001]
  • [Cites] J Neurosci. 2011 Jan 12;31(2):669-77 [21228176.001]
  • [Cites] J Immunol. 2011 May 15;186(10 ):5738-48 [21471445.001]
  • [Cites] Mucosal Immunol. 2014 Jan;7(1):68-77 [23632327.001]
  • [Cites] J Immunol. 2014 Feb 15;192(4):1449-58 [24431229.001]
  • [Cites] Immunol Rev. 2005 Oct;207:229-41 [16181340.001]
  • [Cites] PLoS One. 2015 Jun 15;10(6):e0128945 [26075905.001]
  • [Cites] J Immunol. 2012 Oct 1;189(7):3734-40 [22914048.001]
  • [Cites] Immunity. 2012 May 25;36(5):755-68 [22608495.001]
  • [Cites] J Pathol. 2005 Sep;207(1):32-42 [16025436.001]
  • [Cites] Nat Protoc. 2006;1(4):1810-9 [17487163.001]
  • [Cites] J Neurochem. 2007 Aug;102(3):627-45 [17442053.001]
  • [Cites] Brain Behav Immun. 2010 May;24(4):641-51 [20138983.001]
  • [Cites] J Exp Med. 2003 May 5;197(9):1073-81 [12732654.001]
  • [Cites] Neurobiol Aging. 2007 Oct;28(10 ):1507-21 [16959379.001]
  • [Cites] J Neurochem. 2009 Sep;110(6):1931-41 [19627446.001]
  • [Cites] Genes Dev. 2014 Oct 1;28(19):2134-50 [25274726.001]
  • [Cites] Cell. 2006 Jul 14;126(1):205-18 [16839887.001]
  • [Cites] Nature. 2004 Nov 4;432(7013):59-67 [15378069.001]
  • [Cites] Trends Mol Med. 2011 Feb;17(2):57-64 [21163704.001]
  • [Cites] Genomics. 2010 Aug;96(2):82-91 [20435134.001]
  • [Cites] J Immunol. 2010 Jul 15;185(2):974-81 [20574004.001]
  • [Cites] Immunity. 2012 May 25;36(5):782-94 [22560444.001]
  • [Cites] Blood. 2011 Oct 13;118(15):4199-208 [21846901.001]
  • [Cites] J Immunol Methods. 2006 Jan 20;308(1-2):241-50 [16376371.001]
  • [Cites] Nat Rev Immunol. 2003 Jun;3(6):472-82 [12776207.001]
  • (PMID = 28486971.001).
  • [ISSN] 1742-2094
  • [Journal-full-title] Journal of neuroinflammation
  • [ISO-abbreviation] J Neuroinflammation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


3. Singh AK, Novakova L, Axelsson M, Malmeström C, Zetterberg H, Lycke J, Cardell SL: High Interferon-γ Uniquely in Vδ1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple Sclerosis. Front Immunol; 2017;8:260

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High Interferon-γ Uniquely in Vδ1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple Sclerosis.
  • We have identified a population of T lymphocytes in peripheral blood, Vδ1 TCRγδ T lymphocytes, which unexpectedly was uniquely expressing high production of interferon-γ in newly diagnosed, untreated multiple sclerosis (MS) patients.
  • IFN-γ production in this population distinctly correlated to parameters of clinical disease activity, inflammation, and neuronal damage.
  • A biomarker and early sign of demyelinating disease in MS is much warranted and would help identify immunopathogenesis and prognosis of disease as well as monitor success with adequate treatment.
  • The present study identifies the Vδ1 T lymphocytes as an early marker of MS and a possible link to understanding the disease etiology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Immunol. 2006 May;43(12):2002-11 [16423401.001]
  • [Cites] J Neuroimmunol. 1992 Oct;40(2-3):211-8 [1430152.001]
  • [Cites] J Exp Med. 2003 Aug 4;198(3):391-7 [12900516.001]
  • [Cites] Neuroimmunomodulation. 2015;22(3):181-95 [24852748.001]
  • [Cites] J Immunol. 2016 Feb 15;196 (4):1933-42 [26755823.001]
  • [Cites] J Exp Med. 2004 Jul 5;200(1):79-87 [15238607.001]
  • [Cites] Immunity. 2013 Dec 12;39(6):1032-42 [24239091.001]
  • [Cites] Eur J Immunol. 1999 May;29(5):1667-75 [10359121.001]
  • [Cites] Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):13073-8 [23878218.001]
  • [Cites] J Exp Med. 2004 Apr 5;199(7):947-57 [15051763.001]
  • [Cites] Mol Ther. 2014 Aug;22(8):1416-22 [24895997.001]
  • [Cites] Immunity. 2009 Aug 21;31(2):331-41 [19682929.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8389-94 [12829791.001]
  • [Cites] Clin Exp Immunol. 2009 Sep;157(3):385-94 [19664147.001]
  • [Cites] Neurology. 2009 Dec 1;73(22):1914-22 [19949037.001]
  • [Cites] Nature. 2010 Oct 21;467(7318):967-71 [20962846.001]
  • [Cites] Blood. 2009 Jun 25;113(26):6611-8 [19395673.001]
  • [Cites] Nat Immunol. 2012 Oct;13(10):991-9 [22961052.001]
  • [Cites] Scand J Immunol. 1989 Dec;30(6):665-72 [2481336.001]
  • [Cites] Acta Neurol Scand. 2017 Jan;135(1):17-24 [27558404.001]
  • [Cites] Ann Neurol. 2011 Feb;69(2):292-302 [21387374.001]
  • [Cites] Eur J Immunol. 1999 Dec;29(12):4060-71 [10602017.001]
  • [Cites] Eur J Immunol. 2012 Sep;42(9):2505-10 [22829134.001]
  • [Cites] Immunology. 2015 Sep;146(1):1-10 [26032048.001]
  • [Cites] Nat Immunol. 2011 Mar;12(3):255-63 [21278737.001]
  • [Cites] J Virol. 1996 Jun;70(6):3545-50 [8648688.001]
  • [Cites] J Immunol. 2008 Sep 15;181(6):3750-4 [18768826.001]
  • [Cites] Eur J Immunol. 2009 Jul;39(7):1794-806 [19544311.001]
  • [Cites] Trends Mol Med. 2015 Apr;21(4):233-44 [25771098.001]
  • [Cites] Lancet. 1987 Apr 18;1(8538):893-5 [2882294.001]
  • [Cites] Neurology. 2003 Dec 23;61(12):1720-5 [14694036.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 15;89(10):4588-92 [1374907.001]
  • [Cites] Curr Mol Med. 2009 Feb;9(1):15-22 [19199938.001]
  • [Cites] Nat Immunol. 2011 Jun;12(6):568-75 [21516111.001]
  • [Cites] Nat Immunol. 2011 Jun;12(6):560-7 [21516112.001]
  • [Cites] Front Immunol. 2015 Sep 30;6:503 [26483793.001]
  • [Cites] N Engl J Med. 2006 Mar 2;354(9):899-910 [16510744.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Feb 1;90(3):923-7 [8430106.001]
  • [Cites] J Neurosci Methods. 1994 Mar;51(2):197-204 [8051950.001]
  • [Cites] J Immunol. 2009 Dec 1;183(11):7169-77 [19890056.001]
  • [Cites] J Exp Med. 2010 Apr 12;207(4):807-21 [20368575.001]
  • [Cites] Acta Neuropathol. 2013 Oct;126(4):501-15 [23934116.001]
  • [Cites] Eur J Immunol. 2014 Oct;44(10):3119-28 [25043505.001]
  • [Cites] Nat Rev Immunol. 2013 Feb;13(2):88-100 [23348415.001]
  • [Cites] Clin Immunol. 2015 Nov;161(1):51-8 [26143623.001]
  • [Cites] JAMA Neurol. 2013 Mar 1;70(3):345-51 [23599932.001]
  • [Cites] Neurology. 2009 Jun 2;72(22):1922-30 [19487650.001]
  • [Cites] Immunol Today. 1989 Jun;10(6):186-8 [2526644.001]
  • [Cites] PLoS One. 2015 Sep 14;10(9):e0137429 [26367776.001]
  • [Cites] Annu Rev Immunol. 2014;32:257-81 [24438352.001]
  • [Cites] Eur J Immunol. 2010 Aug;40(8):2174-81 [20486123.001]
  • [Cites] Immunity. 2014 May 15;40(5):785-800 [24816404.001]
  • [Cites] Nat Immunol. 2007 Sep;8(9):913-9 [17712344.001]
  • [Cites] Annu Rev Immunol. 2000;18:975-1026 [10837080.001]
  • [Cites] Sci Rep. 2016 Jun 27;6:28484 [27346372.001]
  • (PMID = 28337205.001).
  • [Journal-full-title] Frontiers in immunology
  • [ISO-abbreviation] Front Immunol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Vdelta1 T cells / cerebrospinal fluid / gamma-delta T cells / interferon-gamma / multiple sclerosis / natalizumab
  •  go-up   go-down


Advertisement
4. Marnetto F, Valentino P, Caldano M, Bertolotto A: Detection of potassium channel KIR4.1 antibodies in Multiple Sclerosis patients. J Immunol Methods; 2017 Jun;445:53-58

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of potassium channel KIR4.1 antibodies in Multiple Sclerosis patients.
  • The presence of KIR4.1 antibodies has been proposed to be a characteristic of Multiple Sclerosis (MS).
  • This could have a significant impact on disease management.
  • The aim of this study is to verify the presence of KIR4.1 antibodies in MS patients, by independently replicating the originally-described procedure.
  • Sera of 48 MS patients and 46 HCs were studied in 21 working sessions.
  • In a preliminary analysis, we observed different KIR4.1 antibody levels between MS patients and Healthy Controls (HCs).
  • However, a high variability across working sessions was observed and the sensitivity of the assay was very low.
  • As per these criteria, we detected LG-KIR4.1 antibodies in 28% of MS patients and 5% of HCs.
  • We propose further efforts be made towards the development of a uniform method to establish the detection of KIR4.1 antibodies in MS patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2017 Elsevier B.V. All rights reserved.
  • (PMID = 28300540.001).
  • [ISSN] 1872-7905
  • [Journal-full-title] Journal of immunological methods
  • [ISO-abbreviation] J. Immunol. Methods
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Keywords] NOTNLM ; Acceptance criteria / Antigen purification / ELISA / KIR4.1 antibodies / Multiple sclerosis
  •  go-up   go-down


5. Ayuso T, Aznar P, Soriano L, Olaskoaga A, Roldán M, Otano M, Ajuria I, Soriano G, Lacruz F, Mendioroz M: Vitamin D receptor gene is epigenetically altered and transcriptionally up-regulated in multiple sclerosis. PLoS One; 2017;12(3):e0174726

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin D receptor gene is epigenetically altered and transcriptionally up-regulated in multiple sclerosis.
  • OBJECTIVE: Vitamin D deficiency has been linked to increased risk of multiple sclerosis (MS) and poor outcome.
  • However, the specific role that vitamin D plays in MS still remains unknown.
  • In order to identify potential mechanisms underlying vitamin D effects in MS, we profiled epigenetic changes in vitamin D receptor (VDR) gene to identify genomic regulatory elements relevant to MS pathogenesis.
  • METHODS: Human T cells derived from whole blood by negative selection were isolated in a set of 23 relapsing-remitting MS (RRMS) patients and 12 controls matched by age and gender.
  • CONCLUSIONS: An alternative promoter of the VDR gene shows altered DNA methylation levels in patients with multiple sclerosis, and it is associated with VDR mRNA upregulation.
  • This locus may represent a candidate regulatory element in the genome relevant to MS pathogenesis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2009 Feb 15;182(4):2063-73 [19201859.001]
  • [Cites] Bioinformatics. 2002 Nov;18(11):1427-31 [12424112.001]
  • [Cites] Clin Epigenetics. 2015 Nov 05;7:118 [26550040.001]
  • [Cites] J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):352-6 [17240138.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Ann Neurol. 2011 Feb;69(2):292-302 [21387374.001]
  • [Cites] J Neurol Sci. 2010 Mar 15;290(1-2):16-21 [20064646.001]
  • [Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]
  • [Cites] Autoimmun Rev. 2011 Oct;10(12):733-43 [21621002.001]
  • [Cites] Mol Cell Biol. 2011 Sep;31(17):3653-69 [21746882.001]
  • [Cites] J Neuropathol Exp Neurol. 2013 Feb;72 (2):91-105 [23334593.001]
  • [Cites] PLoS Med. 2015 Aug 25;12(8):e1001866 [26305103.001]
  • [Cites] Gene. 2015 May 1;561(2):171-80 [25682935.001]
  • [Cites] Mult Scler. 2008 Nov;14(9):1220-4 [18653736.001]
  • [Cites] Neurology. 2014 Jul 15;83(3):278-86 [24871874.001]
  • [Cites] Nat Rev Genet. 2008 Jun;9(6):465-76 [18463664.001]
  • [Cites] Neuromolecular Med. 2015 Jun;17(2):83-96 [24652042.001]
  • [Cites] J Neurosci Res. 2007 Jul;85(9):2006-16 [17469138.001]
  • [Cites] Nat Rev Neurol. 2013 Jan;9(1):35-43 [23165337.001]
  • [Cites] J Clin Endocrinol Metab. 2011 Jan;96(1):53-8 [21118827.001]
  • [Cites] Nucleic Acids Res. 2008 Jul 1;36(Web Server issue):W170-5 [18487274.001]
  • [Cites] JAMA Neurol. 2014 Mar;71(3):306-14 [24445558.001]
  • [Cites] Brain. 2009 May;132(Pt 5):1146-60 [19321461.001]
  • [Cites] Am J Physiol Renal Physiol. 2014 Dec 15;307(12):F1412-26 [25339699.001]
  • [Cites] Front Physiol. 2014 Apr 29;5:164 [24808866.001]
  • [Cites] Nat Rev Genet. 2013 Dec;14(12):880-93 [24217315.001]
  • [Cites] Ann Neurol. 2012 Aug;72(2):234-40 [22926855.001]
  • [Cites] J Immunol. 2011 Jan 1;186(1):92-102 [21131423.001]
  • [Cites] Neurologia. 2015 May 11;:null [25976949.001]
  • (PMID = 28355272.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Navas-Madroñal M, Valero-Mut A, Martínez-Zapata MJ, Simón-Talero MJ, Figueroa S, Vidal-Fernández N, López-Góngora M, Escartín A, Querol L: Absence of antibodies against KIR4.1 in multiple sclerosis: A three-technique approach and systematic review. PLoS One; 2017;12(4):e0175538
MedlinePlus Health Information. consumer health - Multiple Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of antibodies against KIR4.1 in multiple sclerosis: A three-technique approach and systematic review.
  • INTRODUCTION: Antibodies targeting the inward-rectifying potassium channel KIR4.1 have been associated with multiple sclerosis (MS) but studies using diverse techniques have failed to replicate this association.
  • We also performed a systematic review to examine the association of anti-KIR4.1 antibodies with MS.
  • METHODS: Serum samples from patients with MS (n = 108) and controls (n = 77) were tested for the presence of anti-KIR4.1 antibodies using three methods:.
  • We developed a systematic review and meta-analysis of the association of anti-KIR4.1 antibodies with MS according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
  • RESULTS: We did not detect anti-KIR4.1 antibodies in the MS patients or in controls using ELISA.
  • Only three studies showed a positive association between anti-KIR4.1 and MS.
  • CONCLUSION: We found no association between anti-KIR4.1 antibody positivity and MS.
  • Although this lack of replication may be due to technical limitations, evidence from our study and others is mounting against the role of KIR4.1 as a relevant MS autoantigen.
  • [MeSH-major] Antibodies / immunology. Multiple Sclerosis / immunology. Potassium Channels, Inwardly Rectifying / immunology

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Neurol. 2014 Aug;13(8):795-806 [25008548.001]
  • [Cites] Autoimmun Rev. 2014 Nov;13(11):1126-37 [25108168.001]
  • [Cites] Neurology. 2013 Sep 10;81(11):956-63 [23921886.001]
  • [Cites] Proc Natl Acad Sci U S A. 2016 Feb 23;113(8):2188-93 [26862169.001]
  • [Cites] Neurol Neuroimmunol Neuroinflamm. 2016 Jul 22;3(5):e263 [27489866.001]
  • [Cites] Neurology. 2014 Feb 11;82(6):470-3 [24415573.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):187-94 [15630459.001]
  • [Cites] Control Clin Trials. 1986 Sep;7(3):177-88 [3802833.001]
  • [Cites] Nat Rev Neurol. 2012 Nov 5;8(11):595-6 [22986435.001]
  • [Cites] Ann Neurol. 2011 Feb;69(2):292-302 [21387374.001]
  • [Cites] Neurology. 2012 Mar 13;78(11):823-32 [22411958.001]
  • [Cites] N Engl J Med. 2008 Feb 14;358(7):676-88 [18272891.001]
  • [Cites] Brain. 2004 Feb;127(Pt 2):269-79 [14662514.001]
  • [Cites] Neurol Neuroimmunol Neuroinflamm. 2014 May 22;1(1):e12 [25340056.001]
  • [Cites] J Clin Invest. 2012 Apr;122(4):1180-8 [22466660.001]
  • [Cites] Mult Scler. 2015 Apr;21(5):572-9 [25392324.001]
  • [Cites] PLoS One. 2015 Jun 11;10(6):e0129503 [26065913.001]
  • [Cites] Mult Scler. 2014 Nov;20(13):1699-703 [24756568.001]
  • [Cites] J Neurocytol. 2003 Jan;32(1):25-38 [14618099.001]
  • [Cites] Worldviews Evid Based Nurs. 2004;1(3):176-84 [17163895.001]
  • [Cites] Clin Immunol. 2015 Nov;161(1):51-8 [26143623.001]
  • [Cites] Nat Rev Neurol. 2012 Nov 5;8(11):613-23 [23045237.001]
  • [Cites] N Engl J Med. 2016 Apr 14;374(15):1495-6 [27074083.001]
  • [Cites] Nat Rev Neurol. 2015 Mar;11(3):134-42 [25686758.001]
  • [Cites] Lancet. 2004 Dec 11-17;364(9451):2106-12 [15589308.001]
  • [Cites] Ann Neurol. 2014 Aug;76(2):231-40 [24909126.001]
  • [Cites] N Engl J Med. 2012 Jul 12;367(2):115-23 [22784115.001]
  • [Cites] N Engl J Med. 2016 Apr 14;374(15):1496-8 [27074084.001]
  • [Cites] Neuroscience. 2004;129(4):905-13 [15561407.001]
  • [Cites] Ann Neurol. 2014 Jun;75(6):810-28 [24777949.001]
  • [Cites] PLoS Med. 2009 Jul 21;6(7):e1000097 [19621072.001]
  • (PMID = 28414733.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Autoantigens; 0 / Kcnj10 (channel); 0 / Potassium Channels, Inwardly Rectifying
  •  go-up   go-down


7. Preiningerova JL, Vachova M: Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord; 2017 Jan;10(1):67-75

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Daclizumab high-yield process in the treatment of relapsing-remitting multiple sclerosis.
  • Daclizumab is a humanized monoclonal antibody that binds to the α subunit (CD25) of the interleukin-2 receptor and favorably modulates the immune environment in multiple sclerosis (MS).
  • Blockage of CD25, among other effects, causes expansion and enhanced function of regulatory CD56<sup>bright</sup> natural killer cells, which seems to be the leading mechanism of action in MS.
  • Phase II and III clinical trials have demonstrated that monthly subcutaneous injections of daclizumab high yield process (DAC HYP) 150 mg in patients with relapsing MS led to a significant reduction of annualized relapse rate and decreased number of contrast-enhanced lesions on brain magnetic resonance imaging.
  • This review summarizes the development of and clinical experience with daclizumab in MS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2007 Sep;39(9):1074-82 [17676041.001]
  • [Cites] Clin Pharmacokinet. 2016 Aug;55(8):943-55 [26873229.001]
  • [Cites] Nat Rev Immunol. 2012 Feb 17;12(3):180-90 [22343569.001]
  • [Cites] Drugs. 1999 Dec;58(6):1029-42 [10651389.001]
  • [Cites] Immunity. 2013 Jan 24;38(1):13-25 [23352221.001]
  • [Cites] Arch Neurol. 2009 Apr;66(4):483-9 [19364933.001]
  • [Cites] Clin Pharmacol. 2016 Feb 11;8:9-13 [26929672.001]
  • [Cites] N Engl J Med. 2015 Oct 8;373(15):1418-28 [26444729.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8705-8 [15161974.001]
  • [Cites] Lancet. 2013 Jun 22;381(9884):2167-75 [23562009.001]
  • [Cites] J Immunol. 2010 Jul 15;185(2):1311-20 [20543101.001]
  • [Cites] Neurology. 2013 Jan 29;80(5):453-7 [23303850.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5941-6 [16585503.001]
  • [Cites] Immunol Rev. 2011 May;241(1):63-76 [21488890.001]
  • [Cites] Neurology. 2011 Nov 22;77(21):1877-86 [22076546.001]
  • [Cites] Lancet Neurol. 2014 May;13(5):472-81 [24656609.001]
  • [Cites] Neurotherapeutics. 2013 Jan;10(1):55-67 [23055048.001]
  • [Cites] Nat Rev Neurol. 2013 Jul;9(7):394-404 [23732529.001]
  • [Cites] Clin Neurol Neurosurg. 2004 Jun;106(3):218-22 [15177771.001]
  • [Cites] Neurology. 2014 Mar 18;82(11):984-8 [24532277.001]
  • [Cites] Lancet Neurol. 2010 Apr;9(4):381-90 [20163990.001]
  • [Cites] Immunol Today. 1993 Jun;14(6):264-70 [8397768.001]
  • [Cites] Adv Ther. 2016 Jul;33(7):1231-45 [27251051.001]
  • [Cites] Neurology. 2016 Mar 1;86(9):847-55 [26843560.001]
  • [Cites] Arch Neurol. 2009 Apr;66(4):471-9 [19364932.001]
  • [Cites] J Clin Immunol. 2007 Jan;27(1):1-18 [17216565.001]
  • [Cites] Ann Neurol. 2004 Dec;56(6):864-7 [15499632.001]
  • [Cites] Neurotherapeutics. 2013 Jan;10 (1):77-88 [23271506.001]
  • [Cites] Med Immunol. 2006 Aug 14;5:3 [16907989.001]
  • [Cites] BMC Neurol. 2016 Jul 26;16:117 [27461166.001]
  • [Cites] Neurology. 2007 Aug 21;69(8):785-9 [17709711.001]
  • [Cites] Nat Med. 2011 May;17(5):604-9 [21532597.001]
  • [Cites] Eur J Neurol. 2016 Feb;23(2):412-5 [26806217.001]
  • (PMID = 28450896.001).
  • [ISSN] 1756-2856
  • [Journal-full-title] Therapeutic advances in neurological disorders
  • [ISO-abbreviation] Ther Adv Neurol Disord
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Keywords] NOTNLM ; CD25 / daclizumab / interleukin 2 / multiple sclerosis
  •  go-up   go-down


8. Mazdeh M, Noroozi R, Gharesouran J, Sayad A, Komaki A, Eftekharian MM, Habibi M, Toghi M, Taheri M: The Importance of VEGF-KDR Signaling Pathway Genes should Not Be Ignored When the Risk of Developing Multiple Sclerosis is Taken into Consideration. J Mol Neurosci; 2017 May;62(1):73-78

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Importance of VEGF-KDR Signaling Pathway Genes should Not Be Ignored When the Risk of Developing Multiple Sclerosis is Taken into Consideration.
  • Vascular endothelial growth factor (VEGF) and its receptor kinase insert domain-containing receptor (KDR) pathway trigger the process of angiogenesis as well as inflammation, which contributes to the development and progression of demyelinating lesions in multiple sclerosis.
  • This work is a case-control study comprising of a total of 400 subjects with multiple sclerosis and 400 healthy controls.
  • A significantly higher frequency of the T allele and TT genotype of the VEGF 936C > T (rs3025039) polymorphism was found in the multiple sclerosis group than in the healthy control group (P = 0.01 [OR = 1.41] and P = 0.01 [OR = 3.12], respectively).
  • Taken together, the results of the present study suggests that the T allele of the rs3025039 in VEGF gene could be considered a risk factor for developing multiple sclerosis in the Iranian population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28401369.001).
  • [ISSN] 1559-1166
  • [Journal-full-title] Journal of molecular neuroscience : MN
  • [ISO-abbreviation] J. Mol. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; KDR / Multiple sclerosis / Polymorphism / VEGF
  •  go-up   go-down


9. Zandee SEJ, O'Connor RA, Mair I, Leech MD, Williams A, Anderton SM: IL-10-producing, ST2-expressing Foxp3&lt;sup&gt;+&lt;/sup&gt; T cells in multiple sclerosis brain lesions. Immunol Cell Biol; 2017 May;95(5):484-490

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IL-10-producing, ST2-expressing Foxp3<sup>+</sup> T cells in multiple sclerosis brain lesions.
  • CD4<sup>+</sup>Foxp3<sup>+</sup> T regulatory (Treg) cells provide a key defence against inflammatory disease, but also have an ability to produce pro-inflammatory cytokines.
  • The evidence for these two possibilities in multiple sclerosis (MS) is controversial.
  • We show that Foxp3<sup>+</sup> cells in the brains of MS patients predominantly produce interleukin-10 (IL-10) and show high expression of the IL-33 receptor ST2 (associated with potent Treg function), indicating that Treg in the inflamed brain maintain their suppressive function.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunology. 2008 Oct;125(2):178-83 [18422560.001]
  • [Cites] Clin Exp Immunol. 1990 Aug;81(2):301-5 [2117510.001]
  • [Cites] Nat Neurosci. 2013 Sep;16(9):1211-8 [23872599.001]
  • [Cites] J Immunol. 2007 Jul 15;179(2):958-66 [17617587.001]
  • [Cites] J Immunol. 2007 Jul 1;179(1):154-61 [17579033.001]
  • [Cites] Nat Genet. 2001 Jan;27(1):20-1 [11137993.001]
  • [Cites] Eur J Immunol. 2012 Jul;42(7):1804-14 [22585447.001]
  • [Cites] Eur J Immunol. 2005 Nov;35(11):3343-52 [16206232.001]
  • [Cites] Blood. 2006 Jul 1;108(1):253-61 [16537805.001]
  • [Cites] Nat Immunol. 2009 Sep;10(9):1000-7 [19633673.001]
  • [Cites] J Immunol. 2005 Sep 1;175(5):3025-32 [16116190.001]
  • [Cites] PLoS Pathog. 2015 Feb 06;11(2):e1004607 [25659095.001]
  • [Cites] Nature. 2014 Sep 25;513(7519):564-8 [25043027.001]
  • [Cites] Clin Immunol. 2012 Mar;142(3):308-19 [22189043.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4793-8 [19273860.001]
  • [Cites] Immunity. 2011 Apr 22;34(4):566-78 [21511185.001]
  • [Cites] J Exp Med. 1985 Jan 1;161(1):72-87 [3871469.001]
  • [Cites] Clin Exp Immunol. 2007 Mar;147(3):412-8 [17302889.001]
  • [Cites] J Immunol. 2014 Oct 15;193(8):4010-20 [25217167.001]
  • [Cites] J Immunol. 2013 Feb 1;190(3):1076-84 [23277487.001]
  • [Cites] PLoS One. 2016 Aug 22;11(8):e0161507 [27548066.001]
  • [Cites] Am J Pathol. 2008 Jan;172(1):146-55 [18156204.001]
  • [Cites] Eur J Immunol. 2012 May;42(5):1174-9 [22539291.001]
  • [Cites] Curr Opin Neurol. 2008 Jun;21(3):248-54 [18451706.001]
  • [Cites] Neurology. 1996 Dec;47(6):1531-4 [8960740.001]
  • [Cites] Nat Med. 2011 Jun;17(6):673-5 [21540856.001]
  • [Cites] J Immunol. 2007 Jun 1;178(11):6725-9 [17513718.001]
  • [Cites] J Exp Med. 2004 Apr 5;199(7):971-9 [15067033.001]
  • [Cites] Annu Rev Immunol. 2001;19:163-96 [11244034.001]
  • [Cites] J Exp Med. 2007 Jan 22;204(1):33-9 [17200409.001]
  • (PMID = 28169287.001).
  • [ISSN] 1440-1711
  • [Journal-full-title] Immunology and cell biology
  • [ISO-abbreviation] Immunol. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Farrokhi M, Masoudifar A, Derakhshan A, Saadatmand S, Rouhi-Boroujeni H, Etemadifar M, Rezaei-Zarji S, Javid A, Nobakht R, Deyhimi M, Ekramnia A, Ebrahimi M, Sheikh S, Ansaripour S, Amani-Beni A, Jahanbani-Ardakani H: The Association of Interleukin-16 Gene Polymorphisms with IL-16 Serum Levels and Risk of Multiple Sclerosis. Immunol Invest; 2017 Feb 02;:1-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Association of Interleukin-16 Gene Polymorphisms with IL-16 Serum Levels and Risk of Multiple Sclerosis.
  • BACKGROUND: Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and neurodegenerative disease of the central nervous system (CNS) that is immunologically mediated in genetically susceptible individuals.
  • Single-nucleotide polymorphisms (SNPs) in the IL-16 gene may lead to altered cytokine expression or biological activity, and these variations may modulate an individual's risk for MS.
  • To test this hypothesis, we investigated association of IL-16 gene SNPs (i.e., rs4072111 C/T, rs11556218 G/T, and rs4778889 C/T) and serum IL-16 levels with risk of MS in an Iranian population.
  • METHODS: We analyzed the three SNPs of IL-16 in 250 MS patients and 400 healthy controls using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
  • The serum level of IL-16 was assessed by enzyme-linked immunosorbent assay (ELISA).
  • RESULTS: The IL-16 rs4072111C/T genotype and allele frequencies showed significantly differences between MS patients and controls (p < 0.01).
  • The mean serum levels of IL-16 in MS patients were significantly higher in MS patients compared to healthy controls (p ≤ 0.01).
  • CONCLUSION: In summary, the present study provides the first evidence that the rs11556218T/G and rs4072111C/T polymorphisms of IL-16 gene were significantly associated with increased risk of MS.
  • These results suggest that rs11556218T/G, rs4072111C/T, and rs4778889T/C polymorphisms of IL-16 may contribute to susceptibility to MS through increased expression of IL-16 levels.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28151028.001).
  • [ISSN] 1532-4311
  • [Journal-full-title] Immunological investigations
  • [ISO-abbreviation] Immunol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; ELISA / interleukin-16 / multiple sclerosis / polymerase chain reaction / polymorphism
  •  go-up   go-down






Advertisement